Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Peterlin, Pierre  [Clear All Filters]
2024
Jullien M, Guillaume T, Le Bourgeois A, Peterlin P, Garnier A, Eveillard M, Le Bris Y, Bouzy S, Tessoulin B, Gastinne T, et al. Phase I study of zoledronic acid combined with escalated doses of interleukine-2 for early in vivo generation of Vγ9Vδ2 T-cells after haploidentical stem cell transplant with posttransplant cyclophosphamide. Am J Hematol. 2024.
2023
Peterlin P, Le Bris Y, Turlure P, Chevallier P, Ménard A, Gourin M-P, Dumas P-Y, Thépot S, Berceanu A, Park S, et al. CPX-351 in higher risk myelodysplastic syndrome and chronic myelomonocytic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Haematol. 2023.
Le Bourgeois A, Jullien M, Garnier A, Peterlin P, Béné MC, Guillaume T, Chevallier P. Post-transplant cyclophosphamide as sole GHVD prophylaxis after matched reduced-intensity conditioning allotransplant. Clin Transl Med. 2023;13(4):e1242.
2022
Jullien M, Le Bourgeois A, Coste-Burel M, Peterlin P, Garnier A, Rimbert M, Imbert B-M, Le Gouill S, Moreau P, Mahe B, et al. B-cell aplasia is the most powerful predictive marker for poor humoral response after BNT162b2 mRNA SARS-CoV-2 vaccines in recipients of allogeneic hematopoietic stem cell transplantation. Transplant Cell Ther. 2022.
Chevallier P, Jullien M, Peterlin P, Garnier A, Le Bourgeois A, Coste-Burel M, Béné MC, Guillaume T. Effectiveness of a third dose of BNT162b2 anti-SARS-CoV-2 mRNA vaccine over a 6-month follow-up period in allogenic hematopoietic stem cells recipients. Hematol Oncol. 2022.
2021
Jullien M, Orvain C, Berceanu A, Couturier M-A, Guillaume T, Peterlin P, Garnier A, Le Bourgeois A, Klemencie M, Schmidt A, et al. Early Post-Transplant Serum Ferritin Levels Predict Survivals in Recipients of Haploidentical Stem Cell Transplantation Using PTCY as GVHD Prophylaxis. Transplant Cell Ther. 2021.
Jullien M, Orvain C, Berceanu A, Couturier M-A, Guillaume T, Peterlin P, Garnier A, Le Bourgeois A, Klemencie M, Schmidt A, et al. Impact of allogeneic stem cell transplantation comorbidity indexes after haplotransplant using post-transplant cyclophosphamide. Cancer Med. 2021.
Bouvier A, Hamel J-F, Delaunay J, Delabesse E, Dumas P-Y, Ledoux MPierre, Peterlin P, Luquet I, Guepin GRoth, Bulabois CEric, et al. Molecular classification and prognosis in younger adults with acute myeloid leukemia patients and intermediate-risk cytogenetics treated or not by gemtuzumab ozogamycin: final results of the GOELAMS/FILO AML 2006-IR trial. Eur J Haematol. 2021.
Guillaume T, Thépot S, Peterlin P, Ceballos P, Le Bourgeois A, Garnier A, Orvain C, Giltat A, François S, Le Bris Y, et al. Prophylactic or preemptive low-dose azacitidine and donor lymphocyte infusion to prevent disease relapse following allogeneic transplantation in patients with high risk acute myeloid leukemia or myelodysplastic syndrome. Transplant Cell Ther. 2021.
2020
Laurent V, Fronteau C, Antier C, Dupuis P, Tessoulin B, Gastinne T, Mahe B, Blin N, Dubruille V, Lok A, et al. Autologous stem-cell collection following VTD or VRD induction therapy in multiple myeloma: a single-center experience. Bone Marrow Transplant. 2020.
Chevallier P, Berceanu A, Peterlin P, Garnier A, Le Bourgeois A, Imbert B-M, Daguindau E, Mahe B, Dubruille V, Blin N, et al. Grade 2 acute GVHD is a factor of good prognosis in patients receiving peripheral blood stem cells haplo-transplant with post-transplant cyclophosphamide. Acta Oncol. 2020:1-9.
2019
Peterlin P, Gaschet J, Guillaume T, Garnier A, Eveillard M, Le Bourgeois A, Chérel M, Debord C, Le Bris Y, Theisen O, et al. FLT3 ligand plasma levels have no impact on outcomes after allotransplant in acute leukemia. Cytokine. 2019;120:85-87.
Bouard L, Guillaume T, Peterlin P, Garnier A, Le Bourgeois A, Duquenne A, Mahe B, Dubruille V, Blin N, Touzeau C, et al. Influence of donor type (sibling vs matched-unrelated donor vs haplo-identical donor) on outcomes after clofarabine-based reduced-intensity conditioning allograft for myeloid malignancies. Biol Blood Marrow Transplant. 2019.
2018
Guillaume T, Dehame V, Chevallier P, Peterlin P, Garnier A, Gregoire M, Pichinuk E, Rubinstein DB, Wreschner DH. Targeting cell-bound MUC1 on myelomonocytic, monocytic leukemias and phenotypically defined leukemic stem cells with anti-SEA module antibodies. Exp Hematol. 2018.
2014
Le Bourgeois A, Labopin M, Guillaume T, Delaunay J, Foucher Y, Tessoulin B, Malard F, Ayari S, Peterlin P, Derenne S, et al. HHV-6 reactivation before engraftment is strongly predictive of graft failure after double umbilical cord blood allogeneic stem cell transplantation in adults. Exp Hematol. 2014.